-
1
-
-
46449110634
-
One hundred years after ‘carcinoid’: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
-
Yao JC, Hassan M, Phan A et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26(18), 3063-3072 (2008).
-
(2008)
J. Clin. Oncol
, vol.26
, Issue.18
, pp. 3063-3072
-
-
Yao, J.C.1
Hassan, M.2
Phan, A.3
-
2
-
-
55849088735
-
Neuroendocrine tumor epidemiology: Contrasting Norway and North America
-
Hauso O, Gustafsson BI, Kidd M et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 113(10), 2655-2664 (2008).
-
(2008)
Cancer
, vol.113
, Issue.10
, pp. 2655-2664
-
-
Hauso, O.1
Gustafsson, B.I.2
Kidd, M.3
-
3
-
-
55249090388
-
Gastrointestinal neuroendocrine tumors: Pancreatic endocrine tumors
-
Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135(5), 1469-1492 (2008).
-
(2008)
Gastroenterology
, vol.135
, Issue.5
, pp. 1469-1492
-
-
Metz, D.C.1
Jensen, R.T.2
-
4
-
-
33947284588
-
Tumour biology and histopathology of neuroendocrine tumours
-
Klöppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract. Res. Clin. Endocrinol. Metab. 21(1), 15-31 (2007).
-
(2007)
Best Pract. Res. Clin. Endocrinol. Metab
, vol.21
, Issue.1
, pp. 15-31
-
-
Klöppel, G.1
-
5
-
-
79959246002
-
Metastatic and locally advanced pancreatic endocrine carcinomas: Analysis of factors associated with disease progression
-
Panzuto F, Boninsegna L, Fazio N et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J. Clin. Oncol. 29(17), 2372-2377 (2011).
-
(2011)
J. Clin. Oncol
, vol.29
, Issue.17
, pp. 2372-2377
-
-
Panzuto, F.1
Boninsegna, L.2
Fazio, N.3
-
6
-
-
33749032826
-
TNM staging of foregut (Neuro)endocrine tumors: A consensus proposal including a grading system
-
Rindi G, Klöppel G, Alhman H et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 449(4), 395-401 (2006).
-
(2006)
Virchows Arch
, vol.449
, Issue.4
, pp. 395-401
-
-
Rindi, G.1
Klöppel, G.2
Alhman, H.3
-
7
-
-
0030963446
-
Positional cloning of the gene for multiple endocrine neoplasiatype 1
-
Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasiatype 1. Science 276(5311), 404-407 (1997).
-
(1997)
Science
, vol.276
, Issue.5311
, pp. 404-407
-
-
Chandrasekharappa, S.C.1
Guru, S.C.2
Manickam, P.3
-
9
-
-
79952279828
-
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors
-
Jiao Y, Shi C, Edil BH et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331(6021), 1199-1203 (2011).
-
(2011)
Science
, vol.331
, Issue.6021
, pp. 1199-1203
-
-
Jiao, Y.1
Shi, C.2
Edil, B.H.3
-
10
-
-
0033534510
-
Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription
-
Agarwal SK, Guru SC, Heppner C et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 96(1), 143-152 (1999).
-
(1999)
Cell
, vol.96
, Issue.1
, pp. 143-152
-
-
Agarwal, S.K.1
Guru, S.C.2
Heppner, C.3
-
11
-
-
0030748590
-
Novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications
-
Chung DC, Smith AP, Louis DN, Graeme- Cook F, Warshaw AL, Arnold A. A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. J. Clin. Invest. 100(2), 404-410 (1997).
-
(1997)
J. Clin. Invest
, vol.100
, Issue.2
, pp. 404-410
-
-
Chung, D.C.1
Smith, A.P.2
Louis, D.N.3
Graeme-Cook, F.4
Warshaw, A.L.5
Arnold, A.A.6
-
12
-
-
70349527869
-
A simplified prognostic system for resected pancreatic neuroendocrine neoplasms
-
Ballian N, Loeffler AG, Rajamanickam V, Norstedt PA, Weber SM, Cho CS. A simplified prognostic system for resected pancreatic neuroendocrine neoplasms. HPB (Oxford) 11(5), 422-428 (2009).
-
(2009)
HPB (Oxford)
, vol.11
, Issue.5
, pp. 422-428
-
-
Ballian, N.1
Loeffler, A.G.2
Rajamanickam, V.3
Norstedt, P.A.4
Weber, S.M.5
Cho, C.S.6
-
13
-
-
0031867308
-
Isolated liver metastases from neuroendocrine tumors: Does resection prolong survival
-
Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J. Am. Coll. Surg. 187(1), 88-92 (1998).
-
(1998)
J. Am. Coll. Surg
, vol.187
, Issue.1
, pp. 88-92
-
-
Chen, H.1
Hardacre, J.M.2
Uzar, A.3
Cameron, J.L.4
Choti, M.A.5
-
14
-
-
0028891105
-
Hepatic resection for metastatic neuroendocrine carcinomas
-
Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am. J. Surg. 169(1), 36-42 (1995).
-
(1995)
Am. J. Surg
, vol.169
, Issue.1
, pp. 36-42
-
-
Que, F.G.1
Nagorney, D.M.2
Batts, K.P.3
Linz, L.J.4
Kvols, L.K.5
-
15
-
-
20944445859
-
Neuroendocrine hepatic metastases: Does aggressive management improve survival
-
Touzios JG, Kiely JM, Pitt SC et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann. Surg. 241(5), 776-783 (2005).
-
(2005)
Ann. Surg
, vol.241
, Issue.5
, pp. 776-783
-
-
Touzios, J.G.1
Kiely, J.M.2
Pitt, S.C.3
-
16
-
-
35348931680
-
Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: Outcome and prognostic predictors
-
Gomez D, Malik HZ, Al-Mukthar A et al. Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB (Oxford) 9(5), 345-351 (2007).
-
(2007)
HPB (Oxford)
, vol.9
, Issue.5
, pp. 345-351
-
-
Gomez, D.1
Malik, H.Z.2
Al-Mukthar, A.3
-
17
-
-
26444475764
-
Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: Variables affecting response rates and survival
-
Gupta S, Johnson MM, Murthy R et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104(8), 1590-1602 (2005).
-
(2005)
Cancer
, vol.104
, Issue.8
, pp. 1590-1602
-
-
Gupta, S.1
Johnson, M.M.2
Murthy, R.3
-
18
-
-
0032400854
-
Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors
-
Eriksson BK, Larsson EG, Skogseid BM, Löfberg AM, Lörelius LE, Oberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83(11), 2293-2301 (1998).
-
(1998)
Cancer
, vol.83
, Issue.11
, pp. 2293-2301
-
-
Eriksson, B.K.1
Larsson, E.G.2
Skogseid, B.M.3
Löfberg, A.M.4
Lörelius, L.E.5
Oberg, K.E.6
-
19
-
-
44949120870
-
Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: Early results in 148 patients
-
Kennedy AS, Dezarn WA, McNeillie P et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am. J. Clin. Oncol. 31(3), 271-279 (2008).
-
(2008)
Am. J. Clin. Oncol
, vol.31
, Issue.3
, pp. 271-279
-
-
Kennedy, A.S.1
Dezarn, W.A.2
McNeillie, P.3
-
20
-
-
44449085489
-
Liu DM et al. 90Y radioembolization for metastatic neuroendocrine liver tumors: Preliminary results from a multi-institutional experience
-
Rhee TK, Lewandowski RJ, Liu DM et al. 90Y radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann. Surg. 247(6), 1029-1035 (2008).
-
(2008)
Ann. Surg
, vol.247
, Issue.6
, pp. 1029-1035
-
-
Rhee, T.K.1
Lewandowski, R.J.2
-
21
-
-
72949085528
-
Review article: Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours
-
Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment. Pharmacol. Ther. 31(2), 169-188 (2010).
-
(2010)
Aliment. Pharmacol. Ther
, vol.31
, Issue.2
, pp. 169-188
-
-
Modlin, I.M.1
Pavel, M.2
Kidd, M.3
Gustafsson, B.I.4
-
22
-
-
70350442637
-
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group
-
Rinke A, Müller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 27(28), 4656-4663 (2009).
-
(2009)
J. Clin. Oncol
, vol.27
, Issue.28
, pp. 4656-4663
-
-
Rinke, A.1
Müller, H.H.2
Schade-Brittinger, C.3
-
23
-
-
0026530547
-
Streptozocindoxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma
-
Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocindoxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med. 326(8), 519-523 (1992).
-
(1992)
N. Engl. J. Med
, vol.326
, Issue.8
, pp. 519-523
-
-
Moertel, C.G.1
Lefkopoulo, M.2
Lipsitz, S.3
Hahn, R.G.4
Klaassen, D.5
-
24
-
-
14644413806
-
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locallyadvanced and metastatic pancreatic endocrine carcinomas
-
Kouvaraki MA, Ajani JA, Hoff P et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locallyadvanced and metastatic pancreatic endocrine carcinomas. J. Clin. Oncol. 22(23), 4762-4771 (2004).
-
(2004)
J. Clin. Oncol
, vol.22
, Issue.23
, pp. 4762-4771
-
-
Kouvaraki, M.A.1
Ajani, J.A.2
Hoff, P.3
-
25
-
-
0033567934
-
Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma
-
Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86(6), 944-948 (1999).
-
(1999)
Cancer
, vol.86
, Issue.6
, pp. 944-948
-
-
Cheng, P.N.1
Saltz, L.B.2
-
26
-
-
77950367451
-
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
-
Turner NC, Strauss SJ, Sarker D et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br. J. Cancer 102(7), 1106-1112 (2010).
-
(2010)
Br. J. Cancer
, vol.102
, Issue.7
, pp. 1106-1112
-
-
Turner, N.C.1
Strauss, S.J.2
Sarker, D.3
-
27
-
-
34249818466
-
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors
-
Ekeblad S, Sundin A, Janson ET et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin. Cancer Res. 13(10), 2986-2991 (2007).
-
(2007)
Clin. Cancer Res
, vol.13
, Issue.10
, pp. 2986-2991
-
-
Ekeblad, S.1
Sundin, A.2
Janson, E.T.3
-
28
-
-
78650993549
-
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
-
Strosberg JR, Fine RL, Choi J et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117(2), 268-275 (2011).
-
(2011)
Cancer
, vol.117
, Issue.2
, pp. 268-275
-
-
Strosberg, J.R.1
Fine, R.L.2
Choi, J.3
-
29
-
-
58849093671
-
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors
-
Kulke MH, Hornick JL, Frauenhoffer C et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin. Cancer Res. 15(1), 338-345 (2009).
-
(2009)
Clin. Cancer Res
, vol.15
, Issue.1
, pp. 338-345
-
-
Kulke, M.H.1
Hornick, J.L.2
Frauenhoffer, C.3
-
30
-
-
77951940409
-
Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs), a Phase II study
-
Cwikla JB, Sankowski A, Seklecka N et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs), a Phase II study. Ann. Oncol. 21(4), 787-794 (2010).
-
(2010)
Ann. Oncol
, vol.21
, Issue.4
, pp. 787-794
-
-
Cwikla, J.B.1
Sankowski, A.2
Seklecka, N.3
-
31
-
-
79959208861
-
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers
-
Imhof A, Brunner P, Marincek N et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J. Clin. Oncol. 29(17), 2416-2423 (2011).
-
(2011)
J. Clin. Oncol
, vol.29
, Issue.17
, pp. 2416-2423
-
-
Imhof, A.1
Brunner, P.2
Marincek, N.3
-
32
-
-
4344624707
-
Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3] octreotate
-
Teunissen JJ, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3] octreotate. J. Clin. Oncol. 22(13), 2724-2729 (2004).
-
(2004)
J. Clin. Oncol
, vol.22
, Issue.13
, pp. 2724-2729
-
-
Teunissen, J.J.1
Kwekkeboom, D.J.2
Krenning, E.P.3
-
33
-
-
74949122343
-
Pancreatic endocrine tumors: Expression profiling evidences a role for AKT-mTOR pathway
-
Missiaglia E, Dalai I, Barbi S et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J. Clin. Oncol. 28(2), 245-255 (2010).
-
(2010)
J. Clin. Oncol
, vol.28
, Issue.2
, pp. 245-255
-
-
Missiaglia, E.1
Dalai, I.2
Barbi, S.3
-
34
-
-
60749086869
-
Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: Novel chemotherapeutic targets in pancreatic endocrine tumors
-
Bergmann F, Breinig M, Höpfner M et al. Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? Am. J. Gastroenterol. 104(1), 171-181 (2009).
-
(2009)
Am. J. Gastroenterol
, vol.104
, Issue.1
, pp. 171-181
-
-
Bergmann, F.1
Breinig, M.2
Höpfner, M.3
-
35
-
-
0031906775
-
Expression of vascular endothelial growth factor in digestive neuroendocrine tumours
-
Terris B, Scoazec JY, Rubbia L et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 32(2), 133-138 (1998).
-
(1998)
Histopathology
, vol.32
, Issue.2
, pp. 133-138
-
-
Terris, B.1
Scoazec, J.Y.2
Rubbia, L.3
-
36
-
-
79851500081
-
Everolimus for advanced pancreatic neuroendocrine tumors
-
Yao JC, Shah MH, Ito T, Bohas CL et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364(6), 514-523 (2011).
-
(2011)
N. Engl. J. Med
, vol.364
, Issue.6
, pp. 514-523
-
-
Yao, J.C.1
Shah, M.H.2
Ito, T.3
Bohas, C.L.4
-
37
-
-
79851482955
-
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
-
Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364(6), 501-513 (2011).
-
(2011)
N. Engl. J. Med
, vol.364
, Issue.6
, pp. 501-513
-
-
Raymond, E.1
Dahan, L.2
Raoul, J.L.3
-
38
-
-
0016713286
-
Rapamycin (AY-22,989), a new antifungal antibiotic. Fermentation, isolation and characterization
-
Sehgal SN, Baker H, Vézina C. Rapamycin (AY-22,989), a new antifungal antibiotic. Fermentation, isolation and characterization. J. Antibiot. (Tokyo) 28(10), 727-732 (1975).
-
(1975)
J. Antibiot. (Tokyo)
, vol.28
, Issue.10
, pp. 727-732
-
-
Sehgal, S.N.1
Baker, H.2
Vézina, C.3
-
39
-
-
79952361568
-
Everolimus-based, calcineurin-inhibitorfree regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial
-
Budde K, Becker T, Arns W et al. Everolimus-based, calcineurin-inhibitorfree regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377(9768), 837-847 (2011).
-
(2011)
Lancet
, vol.377
, Issue.9768
, pp. 837-847
-
-
Budde, K.1
Becker, T.2
Arns, W.3
-
40
-
-
0019870366
-
Suffness M. New antitumor substances of natural origin. Cancer Treat
-
Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat. Rev. 8(1), 63-87 (1981).
-
(1981)
Rev
, vol.8
, Issue.1
, pp. 63-87
-
-
Douros, J.1
-
41
-
-
79954592882
-
MTOR signaling, function, novel inhibitors, and therapeutic targets
-
Watanabe R, Wei L, Huang J. mTOR signaling, function, novel inhibitors, and therapeutic targets. J. Nucl. Med. 52(4), 497-500 (2011).
-
(2011)
J. Nucl. Med
, vol.52
, Issue.4
, pp. 497-500
-
-
Watanabe, R.1
Wei, L.2
Huang, J.3
-
42
-
-
0034662634
-
Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells
-
von Wichert G, Jehle PM, Hoeflich A et al. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res. 60(16), 4573-4581 (2000).
-
(2000)
Cancer Res
, vol.60
, Issue.16
, pp. 4573-4581
-
-
Von Wichert, G.1
Jehle, P.M.2
Hoeflich, A.3
-
43
-
-
20844435467
-
The NF1 tumor suppressor critically regulates TSC2 and mTOR
-
Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl Acad. Sci. USA 102(24), 8573-8578 (2005).
-
(2005)
Proc. Natl Acad. Sci. USA
, vol.102
, Issue.24
, pp. 8573-8578
-
-
Johannessen, C.M.1
Reczek, E.E.2
James, M.F.3
Brems, H.4
Legius, E.5
Cichowski, K.6
-
44
-
-
0028342578
-
Ampullary carcinoid and neurofibromatosis: Case report and review of the literature. Neth
-
van Basten JP, van Hoek B, de Bruïne A, Arends JW, Stockbrügger RW. Ampullary carcinoid and neurofibromatosis: case report and review of the literature. Neth. J. Med. 44(6), 202-206 (1994).
-
(1994)
J. Med
, vol.44
, Issue.6
, pp. 202-206
-
-
Van Basten, J.P.1
Van Hoek, B.2
De Bruïne, A.3
Arends, J.W.4
Stockbrügger, R.W.5
-
45
-
-
63449098382
-
MTOR inhibitor RAD001 (Everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor
-
Lane HA, Wood JM, McSheehy PM et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin. Cancer Res. 15(5), 1612-1622 (2009).
-
(2009)
Clin. Cancer Res
, vol.15
, Issue.5
, pp. 1612-1622
-
-
Lane, H.A.1
Wood, J.M.2
McSheehy, P.M.3
-
46
-
-
9144233506
-
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells
-
Boulay A, Zumstein-Mecker S, Stephan C et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 64(1), 252-261 (2004).
-
(2004)
Cancer Res
, vol.64
, Issue.1
, pp. 252-261
-
-
Boulay, A.1
Zumstein-Mecker, S.2
Stephan, C.3
-
47
-
-
45149094232
-
Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data
-
Tanaka C, O’Reilly T, Kovarik JM et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J. Clin. Oncol. 26(10), 1596-1602 (2008).
-
(2008)
J. Clin. Oncol
, vol.26
, Issue.10
, pp. 1596-1602
-
-
Tanaka, C.1
O’Reilly, T.2
Kovarik, J.M.3
-
48
-
-
43249131245
-
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A Phase I tumor pharmacodynamic study in patients with advanced solid tumors
-
Tabernero J, Rojo F, Calvo E et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a Phase I tumor pharmacodynamic study in patients with advanced solid tumors. J. Clin. Oncol. 26(10), 1603-1610 (2008).
-
(2008)
J. Clin. Oncol
, vol.26
, Issue.10
, pp. 1603-1610
-
-
Tabernero, J.1
Rojo, F.2
Calvo, E.3
-
49
-
-
33947538050
-
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
-
Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26(13), 1932-1940 (2007).
-
(2007)
Oncogene
, vol.26
, Issue.13
, pp. 1932-1940
-
-
Wan, X.1
Harkavy, B.2
Shen, N.3
Grohar, P.4
Helman, L.J.5
-
50
-
-
32944457518
-
She QB et al. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
-
O’Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66(3), 1500-1508 (2006).
-
(2006)
Cancer Res
, vol.66
, Issue.3
, pp. 1500-1508
-
-
O’Reilly, K.E.1
Rojo, F.2
-
51
-
-
43249086546
-
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
-
O’Donnell A, Faivre S, Burris HA 3rd et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J. Clin. Oncol. 26(10), 1588-1595 (2008).
-
(2008)
J. Clin. Oncol
, vol.26
, Issue.10
, pp. 1588-1595
-
-
O’Donnell, A.1
Faivre, S.2
Burris, H.A.3
-
52
-
-
0035215119
-
Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment. Clin. Pharmacol
-
Kovarik JM, Sabia HD, Figueiredo J et al. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin. Pharmacol. Ther. 70(5), 425-430 (2001).
-
(2001)
Ther
, vol.70
, Issue.5
, pp. 425-430
-
-
Kovarik, J.M.1
Sabia, H.D.2
Figueiredo, J.3
-
53
-
-
26444602978
-
Pharmacokinetic interaction between verapamil and everolimus in healthy subjects
-
Kovarik JM, Beyer D, Bizot MN, Jiang Q, Allison MJ, Schmouder RL. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br. J. Clin. Pharmacol. 60(4), 434-437 (2005).
-
(2005)
Br. J. Clin. Pharmacol
, vol.60
, Issue.4
, pp. 434-437
-
-
Kovarik, J.M.1
Beyer, D.2
Bizot, M.N.3
Jiang, Q.4
Allison, M.J.5
Schmouder, R.L.6
-
54
-
-
52049125970
-
Efficacy of RAD001 (Everolimus) and octreotide LAR in advanced low- to intermediategrade neuroendocrine tumors: Results of a Phase II study
-
Yao JC, Phan AT, Chang DZ et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediategrade neuroendocrine tumors: results of a Phase II study. J. Clin. Oncol. 26(26), 4311-4318 (2008).
-
(2008)
J. Clin. Oncol
, vol.26
, Issue.26
, pp. 4311-4318
-
-
Yao, J.C.1
Phan, A.T.2
Chang, D.Z.3
-
55
-
-
73949088959
-
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A Phase II trial
-
Yao JC, Lombard-Bohas C, Baudin E et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a Phase II trial. J. Clin. Oncol. 28(1), 69-76 (2010).
-
(2010)
J. Clin. Oncol
, vol.28
, Issue.1
, pp. 69-76
-
-
Yao, J.C.1
Lombard-Bohas, C.2
Baudin, E.3
-
56
-
-
85041052883
-
Impact of prior chemotherapy on progression-free survival in patients (Pts) with advanced pancreatic neuroendocrine tumors (pNET
-
Chicago, IL, USA, 4-8 June
-
Pommier RF, Wolin EM, Panneerselvam A, Saletan S, Winkler RE, Van Cutsem E. Impact of prior chemotherapy on progression-free survival in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET). Results from the RADIANT-3 trial. Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2011.
-
(2011)
Results from the RADIANT-3 Trial. Presented At: 2010 ASCO Annual Meeting
-
-
Pommier, R.F.1
Wolin, E.M.2
Panneerselvam, A.3
Saletan, S.4
Winkler, R.E.5
Van Cutsem, E.6
-
57
-
-
85041087255
-
Everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET), impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial
-
Chicago, IL, USA, 4-8 June
-
Shah MH, Lombard-Bohas C, Ito T. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET), impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial. Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2011.
-
(2011)
Presented At: 2010 ASCO Annual Meeting
-
-
Shah, M.H.1
Lombard-Bohas, C.2
Ito, T.3
-
58
-
-
79957566962
-
Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma
-
Porta C, Osanto S, Ravaud A et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur. J. Cancer 47(9), 1287-1298 (2011).
-
(2011)
Eur. J. Cancer
, vol.47
, Issue.9
, pp. 1287-1298
-
-
Porta, C.1
Osanto, S.2
Ravaud, A.3
-
59
-
-
48649107474
-
Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled Phase III trial
-
Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372(9637), 449-456 (2008).
-
(2008)
Lancet
, vol.372
, Issue.9637
, pp. 449-456
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
-
60
-
-
85041047650
-
Everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET), updated results of a randomized, double-blind, placebocontrolled, multicenter, Phase III trial (RADIANT-3).
-
Chicago, IL, USA, 4-8 June
-
Strosberg JR, Lincy J, Winkler RE, Wolin EM, Lee H. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET), updated results of a randomized, double-blind, placebocontrolled, multicenter, Phase III trial (RADIANT-3). Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2011.
-
(2011)
Presented At: 2010 ASCO Annual Meeting
-
-
Strosberg, J.R.1
Lincy, J.2
Winkler, R.E.3
Wolin, E.M.4
Lee, H.5
-
61
-
-
68849123146
-
Everolimus (RAD001), an mTOR inhibitor for the treatment of metastatic renal cell carcinoma
-
Oudard S, Medioni J, Aylllon J et al. Everolimus (RAD001), an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Expert Rev. Anticancer Ther. 9(6), 705-717 (2009).
-
(2009)
Expert Rev. Anticancer Ther
, vol.9
, Issue.6
, pp. 705-717
-
-
Oudard, S.1
Medioni, J.2
Aylllon, J.3
-
62
-
-
85041025665
-
-
Prescribing information for everolimus from the FDA www.accessdata.fda.gov/drugsatfda_docs/label/2011/022344s9s10lbl.pdf
-
-
-
-
63
-
-
85041065367
-
-
Approval of everolimus for advanced renal cell carcinoma after prior therapy with sunitinib or sorafenib by the FDA www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022334s000_SumR.pdf
-
-
-
-
64
-
-
85041047115
-
-
Approval of everolimus for advanced renal cell carcinoma by the EMA www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001038/WC500022815.pdf
-
-
-
-
65
-
-
85041036394
-
-
Approval of everolimus in advanced pancreatic neuroendocrine tumors by the FDA www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/022334s009,s010ltr.pdf
-
-
-
-
66
-
-
85041085591
-
-
Approval of sunitinib in advanced pancreatic neuroendocrine tumors by the FDA www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256237.htm
-
-
-
-
67
-
-
85041057136
-
-
ClinicalTrials.gov. Phase I/II trial of everolimus in combination with temozolomide in advanced PNET http://clinicaltrials.gov/ct2/show/NCT005 76680?cond=pancreas&intr=everolimus& rank=13
-
-
-
-
68
-
-
85041083584
-
-
Phase I trial of everolimus combined with sorafenib in advanced neuroendocrine tumor
-
ClinicalTrials.gov. Phase I trial of everolimus combined with sorafenib in advanced neuroendocrine tumor http://clinicaltrials.gov/ct2/show/NCT00942682?cond=pancreas&intr=everolimus& rank=17
-
-
-
-
69
-
-
85041081463
-
-
Phase I trial of everolimus combined with pasireotide in advanced neuroendocrine tumor
-
ClinicalTrials.gov. Phase I trial of everolimus combined with pasireotide in advanced neuroendocrine tumor http://clinicaltrials.gov/ct2/show/NCT00 804336?cond=pancreas&intr=everolimus &rank=19
-
-
-
-
70
-
-
85041064976
-
-
Phase II trial of everolimus combined with erlotinib in advanced neuroendocrine tumor
-
ClinicalTrials.gov. Phase II trial of everolimus combined with erlotinib in advanced neuroendocrine tumor http://clinicaltrials.gov/ct2/show/NCT00843531?cond=pancreas&intr=everolimus &rank=31
-
-
-
|